Literature DB >> 19034095

Blood transfusion promotes cancer progression: a critical role for aged erythrocytes.

Shir Atzil1, Michal Arad, Ariella Glasner, Noa Abiri, Roi Avraham, Keren Greenfeld, Ella Rosenne, Benzion Beilin, Shamgar Ben-Eliyahu.   

Abstract

BACKGROUND: In cancer patients, allogeneic blood transfusion is associated with poorer prognosis, but the independent effect of the transfusion is controversial. Moreover, mediating mechanisms underlying the alleged cancer-promoting effects of blood transfusion are unknown, including the involvement of donors' leukocytes, erythrocytes, and soluble factors.
METHOD: Two syngeneic tumor models were used in Fischer 344 rats, the MADB106 mammary adenocarcinoma and the CRNK-16 leukemia. Outcomes included host ability to clear circulating cancer cells, and host survival rates. The independent impact of blood transfusion was assessed, and potential deleterious characteristics of the transfusion were studied, including blood storage duration; the role of erythrocytes, leukocyte, and soluble factors; and the kinetics of the effects.
RESULTS: Blood transfusion was found to be an independent and significant risk factor for cancer progression in both models, causing up to a fourfold increase in lung tumor retention and doubling mortality rates. Blood storage time was the critical determinant of these deleterious effects, regardless of whether the transfused blood was allogeneic or autogenic. Surprisingly, aged erythrocytes (9 days and older), rather than leukocytes or soluble factors, mediated the effects, which occurred in both operated and nonoperated animals. The effects of erythrocytes transfusion in the MADB106 model emerged immediately and dissipated within 24 h.
CONCLUSIONS: In rats, transfusion of fresh blood is less harmful than transfusion of stored blood in the context of progressing malignancies. Further studies should address mediating mechanisms through which erythrocytes' storage duration can impact the rate of complications while treating malignant diseases and potentially other pathologies.

Entities:  

Mesh:

Year:  2008        PMID: 19034095      PMCID: PMC2694914          DOI: 10.1097/ALN.0b013e31818ddb72

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  37 in total

1.  Effect of allogeneic blood transfusion on solid tumor growth and pulmonary metastases in mice.

Authors:  S Shirwadkar; M A Blajchman; B Frame; D P Singal
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

Review 2.  Why have meta-analyses of randomized controlled trials of the association between non-white-blood-cell-reduced allogeneic blood transfusion and postoperative infection produced discordant results?

Authors:  E C Vamvakas
Journal:  Vox Sang       Date:  2007-10       Impact factor: 2.144

3.  Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery.

Authors:  L S Jensen; A J Andersen; P M Christiansen; P Hokland; C O Juhl; G Madsen; J Mortensen; C Møller-Nielsen; F Hanberg-Sørensen; M Hokland
Journal:  Br J Surg       Date:  1992-06       Impact factor: 6.939

Review 4.  Perioperative blood transfusion and outcome after resection for colorectal carcinoma.

Authors:  M Chung; O K Steinmetz; P H Gordon
Journal:  Br J Surg       Date:  1993-04       Impact factor: 6.939

5.  Allogeneic blood transfusion-induced enhancement of tumor growth: two animal models showing amelioration by leukodepletion and passive transfer using spleen cells.

Authors:  M A Blajchman; L Bardossy; R Carmen; A Sastry; D P Singal
Journal:  Blood       Date:  1993-04-01       Impact factor: 22.113

Review 6.  Relationship between blood transfusion and tumour behaviour.

Authors:  D M Francis
Journal:  Br J Surg       Date:  1991-12       Impact factor: 6.939

7.  Growth enhancement of established tumors by allogeneic blood transfusion in experimental animals and its amelioration by leukodepletion: the importance of the timing of the leukodepletion.

Authors:  J O Bordin; L Bardossy; M A Blajchman
Journal:  Blood       Date:  1994-07-01       Impact factor: 22.113

8.  Randomised controlled trial comparing transfusion of leucocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer.

Authors:  J G Houbiers; A Brand; L M van de Watering; J Hermans; P J Verwey; A B Bijnen; P Pahlplatz; M Eeftinck Schattenkerk; T Wobbes; J E de Vries
Journal:  Lancet       Date:  1994-08-27       Impact factor: 79.321

9.  Autologous control of a highly malignant syngeneic CRNK-16 leukemia in the rat: a role for NK cells.

Authors:  Roi Avraham; Shelly Inbar; Ella Rosenne; Shamgar Ben-Eliyahu
Journal:  Cancer Immunol Immunother       Date:  2006-02-08       Impact factor: 6.968

10.  Blood transfusions and local tumor recurrence in colorectal cancer. Evidence of a noncausal relationship.

Authors:  O R Busch; W C Hop; R L Marquet; J Jeekel
Journal:  Ann Surg       Date:  1994-12       Impact factor: 12.969

View more
  31 in total

1.  Old blood, new blood or better stored blood?

Authors:  Giancarlo Maria Liumbruno; James P Aubuchon
Journal:  Blood Transfus       Date:  2010-10       Impact factor: 3.443

Review 2.  Ectosomes as immunomodulators.

Authors:  Salima Sadallah; Ceylan Eken; Jürg A Schifferli
Journal:  Semin Immunopathol       Date:  2010-12-07       Impact factor: 9.623

3.  Blood storage duration and biochemical recurrence of cancer after radical prostatectomy.

Authors:  Juan P Cata; Eric A Klein; Gerald A Hoeltge; Jarrod E Dalton; Edward Mascha; Jerome O'Hara; Amanda Russell; Andrea Kurz; Shamgar Ben-Elihayhu; Daniel I Sessler
Journal:  Mayo Clin Proc       Date:  2011-02       Impact factor: 7.616

4.  Arginase as a new concern in blood transfusion.

Authors:  Faustino Mollinedo; Miguel Angel Palomero-Rodríguez; Pilar Sánchez-Conde; Rósula García-Navas; Yolanda Laporta-Báez; Jesús de Vicente-Sánchez; Luis Suarez-Gonzalo
Journal:  Blood Transfus       Date:  2013-05-29       Impact factor: 3.443

Review 5.  [Erythrocyte transfusion: update of the guidelines "therapy with blood components and plasma derivatives"].

Authors:  M Welte
Journal:  Anaesthesist       Date:  2009-11       Impact factor: 1.041

6.  Long-term survival and quality of life after transfusion-associated pulmonary edema in critically ill medical patients.

Authors:  Guangxi Li; Marija Kojicic; Martin K Reriani; Evans R Fernández Pérez; Lokendra Thakur; Rahul Kashyap; Camille M Van Buskirk; Ognjen Gajic
Journal:  Chest       Date:  2009-10-16       Impact factor: 9.410

7.  Effect of storage period of red blood cell suspensions on helper T-cell subpopulations.

Authors:  Salih H Bal; Yasemin Heper; Levent T Kumaş; Furkan Guvenc; Ferah Budak; Güher Göral; Haluk B Oral
Journal:  Blood Transfus       Date:  2017-03-15       Impact factor: 3.443

Review 8.  Red blood cell storage lesion: causes and potential clinical consequences.

Authors:  Tatsuro Yoshida; Michel Prudent; Angelo D'alessandro
Journal:  Blood Transfus       Date:  2019-01       Impact factor: 3.443

Review 9.  Transfusion-related immunomodulation: a reappraisal.

Authors:  Lyla A Youssef; Steven L Spitalnik
Journal:  Curr Opin Hematol       Date:  2017-11       Impact factor: 3.284

Review 10.  Inflammatory response, immunosuppression, and cancer recurrence after perioperative blood transfusions.

Authors:  J P Cata; H Wang; V Gottumukkala; J Reuben; D I Sessler
Journal:  Br J Anaesth       Date:  2013-05       Impact factor: 9.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.